http://orcid.org/0000-0002-9756-128X
REFERENCES
- Trad S, Bodaghi B, Saadoun D. Update on immunological test (Quantiferon-TB gold) contribution in the management of tuberculosis-related ocular inflammation. Ocul Immunol Inflamm. July, 2017;1–8. doi:10.1080/09273948.2017.1332232.
- Weyer K, Gilpin C, Mirzayev F, Gemert WV, World Health Organization. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement. 2011. http://www.ncbi.nlm.nih.gov/books/NBK310677/. Accessed August 9, 2017.
- Balne P, Modi R, Choudhury N, et al. Factors influencing polymerase chain reaction outcomes in patients with clinically suspected ocular tuberculosis. J Ophthalmic Inflamm Infect. 2014;4(1):10. doi:10.1186/1869-5760-4-10.
- Bajgai P, Sharma K, Bansal R, Gupta N, Sharma A, Gupta A. Detection of Mycobacterium tuberculosis genome in subretinal fluid of patients with latent tuberculosis infection. Ocul Immunol Inflamm. 2016;24(6):615–620. doi:10.3109/09273948.2015.1063670.
- Gülbay BE, Gürkan ÖU, Yıldız ÖA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100(10):1834–1842. doi:10.1016/j.rmed.2006.01.014.